The global blood screening market was valued at $2.4 billion in 2022 and is projected to reach $4.9 billion by 2032, registering a CAGR of 7.5% from 2023 to 2032. Blood screening is the process of testing the donated blood prior to transfusion to ensure that recipients receive the safest possible blood products. The objective of blood screening is to detect markers of infection to prevent the release of infected blood and blood components for clinical use. Blood screening strategies are designed to assure the safety of blood units. Based on the screening process, the blood is either used for medical applications or discarded if any infectious pathogen was found in it.
The factors driving the growth of the market include rise in demand for donated blood and blood related products for medical applications, surge in number of blood donations globally, and strict protocols by regulatory body for screening of blood to ensure safe transfusion.
The rise in demand for donated blood and blood-related products for medical applications has emerged as a major driving force behind the growth of the blood screening market. This increased demand can be attributed to several factors, including the growing prevalence of chronic diseases, the expansion of medical procedures and surgeries, and the need for blood transfusions in emergency situations. For instance, according to 2022 report by U.S. Blood Statistics, in U.S. in every 2 second donated blood is used for medical purpose. The demand for blood products has surged, as healthcare systems advance worldwide, creating a significant need for stringent blood screening processes to ensure the safety of both donors and recipients. Blood screening plays a pivotal role in identifying and eliminating infectious agents such as HIV, hepatitis, and other blood-borne pathogens, thereby reducing the risk of transmission and improving the overall safety of blood transfusions. Thus, the rise in demand for donated blood is expected to drive the growth of the blood screening products to ensure safe transfusion of the blood.
Furthermore, the strict protocols of regulatory bodies towards screening of donated blood are also expected to drive the growth of the market. These regulatory frameworks are designed to ensure the safety of donated blood and protect both the donors and recipients. The protocols encompass various aspects of the blood screening process, including donor eligibility criteria, sample collection, testing methodologies, and post-screening measures. By adhering to these rigorous regulations, blood banks and screening facilities can maintain a high level of trust and confidence in the quality of the blood supply. According to 2023 report by World Health Organization, screening for HIV, hepatitis B, hepatitis C, and syphilis in donated blood should be mandatory. The same report mentioned that 99.8% of the donations in high-income countries and 99.9% in upper-middle-income countries are screened following basic quality procedures. Thus, the measures taken by the public and private organizations in regulating and ensuring the blood screening of every donated blood unit is expected to drive the demand for the blood screening products.
In addition, the surge in number of blood donations globally has emerged as a significant driver for the blood screening market. Over the years, there has been a growing awareness about the importance of regular blood donations to meet the increasing demand for blood and its components in healthcare settings, particularly for medical procedures, surgeries, and the treatment of various diseases. For instance, according to World Health Organization, in 2022, a total of 118.8 million blood donations were collected globally. This increased awareness, coupled with advancements in medical technology, has encouraged a substantial rise in voluntary and organized blood donation campaigns worldwide. As a result, the need for rigorous and efficient blood screening procedures has become important to ensure the safety of the donated blood supply. Thus, the rise in blood donations globally is expected to drive the growth of the blood screening market. However, regulatory hurdles and high cost of blood screening instruments are projected to restrain the growth of the market.
The blood screening market is segmented on the basis of product, technology, end use, and region. By product, the market is classified into instruments and kits and reagents. By technology, the market is categorized into NAT technology, immunoassay. By end user, the market is bifurcated into hospitals and blood banks. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global blood screening market include F. Hoffmann-La Roche Ltd., Grifols, S.A., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, DiaSorin S.p.A., Siemens AG, Avioq, Inc, QuidelOrtho Corporation and Alive DX.
The factors driving the growth of the market include rise in demand for donated blood and blood related products for medical applications, surge in number of blood donations globally, and strict protocols by regulatory body for screening of blood to ensure safe transfusion.
The rise in demand for donated blood and blood-related products for medical applications has emerged as a major driving force behind the growth of the blood screening market. This increased demand can be attributed to several factors, including the growing prevalence of chronic diseases, the expansion of medical procedures and surgeries, and the need for blood transfusions in emergency situations. For instance, according to 2022 report by U.S. Blood Statistics, in U.S. in every 2 second donated blood is used for medical purpose. The demand for blood products has surged, as healthcare systems advance worldwide, creating a significant need for stringent blood screening processes to ensure the safety of both donors and recipients. Blood screening plays a pivotal role in identifying and eliminating infectious agents such as HIV, hepatitis, and other blood-borne pathogens, thereby reducing the risk of transmission and improving the overall safety of blood transfusions. Thus, the rise in demand for donated blood is expected to drive the growth of the blood screening products to ensure safe transfusion of the blood.
Furthermore, the strict protocols of regulatory bodies towards screening of donated blood are also expected to drive the growth of the market. These regulatory frameworks are designed to ensure the safety of donated blood and protect both the donors and recipients. The protocols encompass various aspects of the blood screening process, including donor eligibility criteria, sample collection, testing methodologies, and post-screening measures. By adhering to these rigorous regulations, blood banks and screening facilities can maintain a high level of trust and confidence in the quality of the blood supply. According to 2023 report by World Health Organization, screening for HIV, hepatitis B, hepatitis C, and syphilis in donated blood should be mandatory. The same report mentioned that 99.8% of the donations in high-income countries and 99.9% in upper-middle-income countries are screened following basic quality procedures. Thus, the measures taken by the public and private organizations in regulating and ensuring the blood screening of every donated blood unit is expected to drive the demand for the blood screening products.
In addition, the surge in number of blood donations globally has emerged as a significant driver for the blood screening market. Over the years, there has been a growing awareness about the importance of regular blood donations to meet the increasing demand for blood and its components in healthcare settings, particularly for medical procedures, surgeries, and the treatment of various diseases. For instance, according to World Health Organization, in 2022, a total of 118.8 million blood donations were collected globally. This increased awareness, coupled with advancements in medical technology, has encouraged a substantial rise in voluntary and organized blood donation campaigns worldwide. As a result, the need for rigorous and efficient blood screening procedures has become important to ensure the safety of the donated blood supply. Thus, the rise in blood donations globally is expected to drive the growth of the blood screening market. However, regulatory hurdles and high cost of blood screening instruments are projected to restrain the growth of the market.
The blood screening market is segmented on the basis of product, technology, end use, and region. By product, the market is classified into instruments and kits and reagents. By technology, the market is categorized into NAT technology, immunoassay. By end user, the market is bifurcated into hospitals and blood banks. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global blood screening market include F. Hoffmann-La Roche Ltd., Grifols, S.A., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, DiaSorin S.p.A., Siemens AG, Avioq, Inc, QuidelOrtho Corporation and Alive DX.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blood screening market analysis from 2022 to 2032 to identify the prevailing blood screening market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the blood screening market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global blood screening market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product
- Instruments
- Kits and Reagents
By End User
- Blood Banks
- Hospitals
By Technology
- NAT Technology
- Type
- Transcription Mediated Amplification (TMA)
- Real time PCR
- NGS
- Immunoassays
- Type
- Enzyme immunoassays (EIAs)
- Chemiluminescent immunoassays (CLIAs)
- Particle agglutination (PA) assays
- Rapid assays
- Western Bloat
- ELSA
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Arabia
- South Africa
- Rest of LAMEA
- Grifols, S.A.
- Abbott Laboratories
- Danaher Corporation
- DiaSorin S.p.A.
- Avioq, Inc.
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Siemens AG
- Alive DX
- QuidelOrtho Corporation.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: BLOOD SCREENING MARKET, BY PRODUCT
CHAPTER 5: BLOOD SCREENING MARKET, BY TECHNOLOGY
CHAPTER 6: BLOOD SCREENING MARKET, BY END USER
CHAPTER 7: BLOOD SCREENING MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Grifols, S.A.
- Abbott Laboratories
- Danaher Corporation
- DiaSorin S.p.A.
- Avioq, Inc.
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Siemens AG
- Alive DX
- QuidelOrtho Corporation.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 240 |
| Published | November 2023 |
| Forecast Period | 2022 - 2032 |
| Estimated Market Value ( USD | $ 2.4 billion |
| Forecasted Market Value ( USD | $ 4.9 billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
